코오롱생명과학

102940KOSDAQ기초 의약물질 제조업

56.9 / 100

Reference Date: 2026-07-24

Financial Score24.5 / 40

News Sentiment18.4 / 25

Momentum7.0 / 20

Disclosure7.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 58.0% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Kolon Life Science operates three business segments: Chemical, SC, and Bio. The Chemical segment, focused on pharmaceutical API production, drives revenue growth due to expanding global pharmaceutical markets and increased outsourcing of raw material production. However, the Bio segment continues to report significant losses.

Number of Employees

454people

Average Salary

60.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.90Industry Average 25.448.0Point

Half of industry avg (excellent)

PBR

0.42Industry Average 1.267.0Point

Half of industry avg (excellent)

ROE

6.81Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

27.50Industry Average 6.620.0Point

4.2x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲29.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲94.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.1% (improving, 3yr)

Detailed News Sentiment

17 totalPositive 6Neutral 2Negative 9Average Sentiment Score 73.5

Negative
3연속 하한가…코오롱티슈진 임상쇼크 사흘째 계속
코오롱티슈진의 임상 실패 소식으로 인해 주가가 연속 하한가를 기록하며 큰 하락을 겪고 있다.
Negative
코오롱티슈진, TG-C 미국 임상 실패 여파에 3거래일째 '下'
코오롱티슈진의 미국 임상 실패로 인해 주가가 3거래일 연속 하한가를 기록했다.
Negative
코오롱티슈진 이틀 연속 하한가…TG-C 美 3상 실패 쇼크 지속
코오롱티슈진의 주가가 이틀 연속 하한가를 기록하며, 미국 임상 3상 실패 소식이 지속적으로 부정적 영향을 미치고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 18,880Won52-week high 70,80052-week low 17,490

1-month return0.0Point

1m -58.04% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 0Negative 1

Negative소송등의판결ㆍ결정(일정금액이상의청구) (화해권고결정)2026-07-03